Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its
Express News | Goldman Sachs Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $7
Maravai LifeSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 -4.89% Goldman Sachs $8 → $7 Maintains Neutral 05/09/2024 35.87% Baird $8 → $10 Maintains
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important
Take Care Before Jumping Onto Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Even Though It's 35% Cheaper
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop over the last 30 days has capped off a tough year
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability -- Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support
Here's Why RGAIA Considers Maravai LifeSciences Holdings' (MRVI) Margin Structure as the Best
Steven Cohen's Strategic Acquisition in Maravai LifeSciences Holdings Inc
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results.Bank of Montreal posted quarterly adjusted
Maravai LifeSciences Shares Fall 16% After Stock-Sale Proposals
By Ben Glickman Shares of Maravai LifeSciences Holdings fell Wednesday after the company registered to sell nearly 10 million shares. The stock was down 16%, to $9.04, in afternoon trading. Shares a
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersInnovative Eyewear (NASDAQ:LUCY) stock increased by 173.2% to $1.12 during Wednesday's regular session. The market value of their outstanding shares is at $19.6 million. Reshape Lifesciences (N
Semler Scientific, Genetic Technologies, ReShape Lifesciences Among Healthcare Movers
Form 144 | Maravai LifeSciences(MRVI.US) Insider Proposes to Sell 16.5 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 28, $Maravai LifeSciences(MRVI.US)$ Insider Maravai Life Sciences Holdings 2, LLC intends to sell 1.53 million shares of its common stock on May 28, with a total market val
Form 144 | Maravai LifeSciences(MRVI.US) Insider Proposes to Sell 90.66 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 28, $Maravai LifeSciences(MRVI.US)$ Insider Maravai Life Sciences Holdings, LLC intends to sell 8.41 million shares of its common stock on May 28, with a total market value
Maravai (MRVI) Advances in RNA Research With New Collaboration
Maravai LifeSciences’ MRVI business, TriLink BioTechnologies, recently partnered with Johns Hopkins University to significantly enhance research in RNA therapeutics.
Investors Interested In Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Revenues
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales ratios (or "P/S") below 3.4x, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) lo
Maravai LifeSciences Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Maravai LifeSciences | 10-Q: Quarterly report
Express News | Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform Rating on the Stock and Raised Its Price Target...